title: Peripheral and central mediators of lipopolysaccharide induced suppression of defensive rage behavior in the cat.
abstract: Based upon recent findings in our laboratory that cytokines microinjected into the medial hypothalamus or periaqueductal gray (PAG) powerfully modulate defensive rage behavior in cat, the present study determined the effects of peripherally released cytokines following lipopolysaccharide (LPS) challenge upon defensive rage. The study involved initial identification of the effects of peripheral administration of LPS upon defensive rage by electrical stimulation from PAG and subsequent determination of the peripheral and central mechanisms governing this process. The results revealed significant elevation in response latencies for defensive rage from 60 to 300 min, post LPS injection, with no detectable signs of sickness behavior present at 60 min. In contrast, head turning behavior elicited by stimulation of adjoining midbrain sites was not affected by LPS administration, suggesting a specificity of the effects of LPS upon defensive rage. Direct administration of LPS into the medial hypothalamus had no effect on defensive rage, suggesting that the effects of LPS were mediated by peripheral cytokines rather than by any direct actions upon hypothalamic neurons. Complete blockade of the suppressive effects of LPS by peripheral pretreatment with an Anti-tumor necrosis factor-alpha (TNFalpha) antibody but not with an anti- interleukin-1 (IL-1) antibody demonstrated that the effects of LPS were mediated through TNF-alpha rather than through an IL-1 mechanism. A determination of the central mechanisms governing LPS suppression revealed that pretreatment of the medial hypothalamus with PGE(2) or 5-HT(1A) receptor antagonists each completely blocked the suppressive effects of LPS, while microinjections of a TNF-alpha antibody into the medial hypothalamus were ineffective. Microinjections of -Iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) benzamide monohydrochloride (p-MPPI) into lateral hypothalamus (to test for anatomical specificity) had no effect upon LPS induced suppression of defensive rage. The results demonstrate that LPS suppresses defensive rage by acting through peripheral TNF-alpha in periphery and that central effects of LPS suppression of defensive rage are mediated through PGE(2) and 5-HT(1A) receptors in the medial hypothalamus.
authors: Department of Neurology and Neurosciences, New Jersey Medical School, University of Medicine and Dentistry, 185 South Orange Avenue, Newark, NJ 07103, USA.
authors: S
authors: S
authors: Bhatt
authors: R S
authors: RS
authors: Bhatt
authors: S S
authors: SS
authors: Zalcman
authors: A
authors: A
authors: Siegel
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D001323:Autoantibodies / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D002415:Cats; D004558:Electric Stimulation; D005260:Female; D019416:Head Movements / Q000187:drug effects / Q000502:physiology; D007031:Hypothalamus / Q000187:drug effects* / Q000502:physiology; D007375:Interleukin-1 / Q000276:immunology / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D010487:Periaqueductal Gray / Q000187:drug effects / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D011889:Rage / Q000187:drug effects* / Q000502:physiology; D018078:Receptors, Prostaglandin E / Q000037:antagonists & inhibitors; D058829:Serotonin 5-HT1 Receptor Antagonists; D012702:Serotonin Antagonists / Q000494:pharmacology; D013997:Time Factors; D014149:Tranquilizing Agents / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism
chemical_list: D000631:Aminopyridines; D001323:Autoantibodies; D007375:Interleukin-1; D008070:Lipopolysaccharides; D010879:Piperazines; D018078:Receptors, Prostaglandin E; D058829:Serotonin 5-HT1 Receptor Antagonists; D012702:Serotonin Antagonists; D014149:Tranquilizing Agents; D014409:Tumor Necrosis Factor-alpha; C087205:4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine